Skip to content

Thermo Fisher Scientific

NYSE: TMO · USD

Thermo Fisher Scientific financials

6 charts

Revenue

USD millions

$11,994M
Thermo Fisher Scientific Revenue. Quarterly values and changes versus the preceding comparable period. Missing values are unavailable.
PeriodRevenue
FY 2009 Q2$2,484.1M; Change unavailable vs FY 2009 Q1
FY 2009 Q3$2,531.1M; +1.9% vs FY 2009 Q2
FY 2009 Q4$2,839.4M; +12.2% vs FY 2009 Q3
FY 2010 Q1$2,675.1M; −5.8% vs FY 2009 Q4
FY 2010 Q2$2,649M; −1.0% vs FY 2010 Q1
FY 2010 Q3$2,683.5M; +1.3% vs FY 2010 Q2
FY 2010 Q4$2,781.1M; +3.6% vs FY 2010 Q3
FY 2011 Q1$2,721.4M; −2.1% vs FY 2010 Q4
FY 2011 Q2$2,897.4M; +6.5% vs FY 2011 Q1
FY 2011 Q3$2,973.5M; +2.6% vs FY 2011 Q2
FY 2011 Q4$3,133.6M; +5.4% vs FY 2011 Q3
FY 2012 Q1$3,100.3M; −1.1% vs FY 2011 Q4
FY 2012 Q2$3,108.1M; +0.3% vs FY 2012 Q1
FY 2012 Q3$3,085.7M; −0.7% vs FY 2012 Q2
FY 2012 Q4$3,259.3M; +5.6% vs FY 2012 Q3
FY 2013 Q1$3,191.5M; −2.1% vs FY 2012 Q4
FY 2013 Q2$3,240.1M; +1.5% vs FY 2013 Q1
FY 2013 Q3$3,191.8M; −1.5% vs FY 2013 Q2
FY 2013 Q4$3,466.9M; +8.6% vs FY 2013 Q3
FY 2014 Q1$3,903.5M; +12.6% vs FY 2013 Q4
FY 2014 Q2$4,321.9M; +10.7% vs FY 2014 Q1
FY 2014 Q3$4,171.4M; −3.5% vs FY 2014 Q2
FY 2014 Q4$4,492.8M; +7.7% vs FY 2014 Q3
FY 2015 Q1$3,918.8M; −12.8% vs FY 2014 Q4
FY 2015 Q2$4,270.9M; +9.0% vs FY 2015 Q1
FY 2015 Q3$4,123.2M; −3.5% vs FY 2015 Q2
FY 2015 Q4$4,652.5M; +12.8% vs FY 2015 Q3
FY 2016 Q1$4,294.8M; −7.7% vs FY 2015 Q4
FY 2016 Q2$4,535.2M; +5.6% vs FY 2016 Q1
FY 2016 Q3$4,490.9M; −1.0% vs FY 2016 Q2
FY 2016 Q4$4,953.2M; +10.3% vs FY 2016 Q3
FY 2017 Q1$4,765M; −3.8% vs FY 2016 Q4
FY 2017 Q2$4,990M; +4.7% vs FY 2017 Q1
FY 2017 Q3$5,116.2M; +2.5% vs FY 2017 Q2
FY 2017 Q4$6,047M; +18.2% vs FY 2017 Q3
FY 2018 Q1$5,853M; −3.2% vs FY 2017 Q4
FY 2018 Q2$6,078M; +3.8% vs FY 2018 Q1
FY 2018 Q3$5,920M; −2.6% vs FY 2018 Q2
FY 2018 Q4$6,507M; +9.9% vs FY 2018 Q3
FY 2019 Q1$6,125M; −5.9% vs FY 2018 Q4
FY 2019 Q2$6,316M; +3.1% vs FY 2019 Q1
FY 2019 Q3$6,272M; −0.7% vs FY 2019 Q2
FY 2019 Q4$6,829M; +8.9% vs FY 2019 Q3
FY 2020 Q1$6,230M; −8.8% vs FY 2019 Q4
FY 2020 Q2$6,917M; +11.0% vs FY 2020 Q1
FY 2020 Q3$8,521M; +23.2% vs FY 2020 Q2
FY 2020 Q4$10,550M; +23.8% vs FY 2020 Q3
FY 2021 Q1$9,906M; −6.1% vs FY 2020 Q4
FY 2021 Q2$9,273M; −6.4% vs FY 2021 Q1
FY 2021 Q3$9,330M; +0.6% vs FY 2021 Q2
FY 2021 Q4$10,702M; +14.7% vs FY 2021 Q3
FY 2022 Q1$11,818M; +10.4% vs FY 2021 Q4
FY 2022 Q2$10,970M; −7.2% vs FY 2022 Q1
FY 2022 Q3$10,677M; −2.7% vs FY 2022 Q2
FY 2022 Q4$11,450M; +7.2% vs FY 2022 Q3
FY 2023 Q1$10,710M; −6.5% vs FY 2022 Q4
FY 2023 Q2$10,687M; −0.2% vs FY 2023 Q1
FY 2023 Q3$10,574M; −1.1% vs FY 2023 Q2
FY 2023 Q4$10,886M; +3.0% vs FY 2023 Q3
FY 2024 Q1$10,345M; −5.0% vs FY 2023 Q4
FY 2024 Q2$10,541M; +1.9% vs FY 2024 Q1
FY 2024 Q3$10,598M; +0.5% vs FY 2024 Q2
FY 2024 Q4$11,395M; +7.5% vs FY 2024 Q3
FY 2025 Q1$10,364M; −9.0% vs FY 2024 Q4
FY 2025 Q2$10,855M; +4.7% vs FY 2025 Q1
FY 2025 Q3$11,122M; +2.5% vs FY 2025 Q2
FY 2025 Q4$12,215M; +9.8% vs FY 2025 Q3
FY 2026 Q1$11,005M; −9.9% vs FY 2025 Q4
FY 2026 Q2$11,994M; +9.0% vs FY 2026 Q1
Jun 27, 2009 through Sep 25, 2026

Free cash flow

USD millions

$1,675M
Thermo Fisher Scientific Free cash flow. Quarterly values and changes versus the preceding comparable period. Missing values are unavailable.
PeriodFree cash flow
FY 2009 Q2$343.5M; Change unavailable vs FY 2009 Q1
FY 2009 Q3$343.8M; +0.1% vs FY 2009 Q2
FY 2009 Q4$456.9M; +32.9% vs FY 2009 Q3
FY 2010 Q1$292.5M; −36.0% vs FY 2009 Q4
FY 2010 Q2$225.3M; −23.0% vs FY 2010 Q1
FY 2010 Q3$368.2M; +63.4% vs FY 2010 Q2
FY 2010 Q4$346.3M; −5.9% vs FY 2010 Q3
FY 2011 Q1$274.9M; −20.6% vs FY 2010 Q4
FY 2011 Q2$295.5M; +7.5% vs FY 2011 Q1
FY 2011 Q3$298.1M; +0.9% vs FY 2011 Q2
FY 2011 Q4$556M; +86.5% vs FY 2011 Q3
FY 2012 Q1$322.6M; −42.0% vs FY 2011 Q4
FY 2012 Q2$442.2M; +37.1% vs FY 2012 Q1
FY 2012 Q3$403.9M; −8.7% vs FY 2012 Q2
FY 2012 Q4$555.7M; +37.6% vs FY 2012 Q3
FY 2013 Q1$232.3M; −58.2% vs FY 2012 Q4
FY 2013 Q2$412.8M; +77.7% vs FY 2013 Q1
FY 2013 Q3$449.2M; +8.8% vs FY 2013 Q2
FY 2013 Q4$634M; +41.1% vs FY 2013 Q3
FY 2014 Q1$-3.5M; −100.6% vs FY 2013 Q4
FY 2014 Q2$813.2M; +23334.3% vs FY 2014 Q1
FY 2014 Q3$585.3M; −28.0% vs FY 2014 Q2
FY 2014 Q4$797M; +36.2% vs FY 2014 Q3
FY 2015 Q1$-17.2M; −102.2% vs FY 2014 Q4
FY 2015 Q2$669.6M; +3993.0% vs FY 2015 Q1
FY 2015 Q3$642.9M; −4.0% vs FY 2015 Q2
FY 2015 Q4$1,098.7M; +70.9% vs FY 2015 Q3
FY 2016 Q1$174M; −84.2% vs FY 2015 Q4
FY 2016 Q2$774.7M; +345.2% vs FY 2016 Q1
FY 2016 Q3$690.8M; −10.8% vs FY 2016 Q2
FY 2016 Q4$1,072.4M; +55.2% vs FY 2016 Q3
FY 2017 Q1$268.1M; −75.0% vs FY 2016 Q4
FY 2017 Q2$760.4M; +183.6% vs FY 2017 Q1
FY 2017 Q3$817.2M; +7.5% vs FY 2017 Q2
FY 2017 Q4$1,651.3M; +102.1% vs FY 2017 Q3
FY 2018 Q1$-40M; −102.4% vs FY 2017 Q4
FY 2018 Q2$1,261M; +3252.5% vs FY 2018 Q1
FY 2018 Q3$1,047M; −17.0% vs FY 2018 Q2
FY 2018 Q4$1,517M; +44.9% vs FY 2018 Q3
FY 2019 Q1$448M; −70.5% vs FY 2018 Q4
FY 2019 Q2$1,074M; +139.7% vs FY 2019 Q1
FY 2019 Q3$901M; −16.1% vs FY 2019 Q2
FY 2019 Q4$1,624M; +80.2% vs FY 2019 Q3
FY 2020 Q1$103M; −93.7% vs FY 2019 Q4
FY 2020 Q2$1,617M; +1469.9% vs FY 2020 Q1
FY 2020 Q3$2,342M; +44.8% vs FY 2020 Q2
FY 2020 Q4$2,753M; +17.5% vs FY 2020 Q3
FY 2021 Q1$1,350M; −51.0% vs FY 2020 Q4
FY 2021 Q2$1,687M; +25.0% vs FY 2021 Q1
FY 2021 Q3$2,126M; +26.0% vs FY 2021 Q2
FY 2021 Q4$1,626M; −23.5% vs FY 2021 Q3
FY 2022 Q1$1,562M; −3.9% vs FY 2021 Q4
FY 2022 Q2$1,022M; −34.6% vs FY 2022 Q1
FY 2022 Q3$1,390M; +36.0% vs FY 2022 Q2
FY 2022 Q4$2,937M; +111.3% vs FY 2022 Q3
FY 2023 Q1$271M; −90.8% vs FY 2022 Q4
FY 2023 Q2$1,256M; +363.5% vs FY 2023 Q1
FY 2023 Q3$2,082M; +65.8% vs FY 2023 Q2
FY 2023 Q4$3,318M; +59.4% vs FY 2023 Q3
FY 2024 Q1$904M; −72.8% vs FY 2023 Q4
FY 2024 Q2$1,659M; +83.5% vs FY 2024 Q1
FY 2024 Q3$1,894M; +14.2% vs FY 2024 Q2
FY 2024 Q4$2,810M; +48.4% vs FY 2024 Q3
FY 2025 Q1$361M; −87.2% vs FY 2024 Q4
FY 2025 Q2$1,105M; +206.1% vs FY 2025 Q1
FY 2025 Q3$1,835M; +66.1% vs FY 2025 Q2
FY 2025 Q4$2,992M; +63.1% vs FY 2025 Q3
FY 2026 Q1$816M; −72.7% vs FY 2025 Q4
FY 2026 Q2$1,675M; +105.3% vs FY 2026 Q1

Net margin

%

14.47%
Thermo Fisher Scientific Net margin. Reported fiscal history.
Fiscal period%
FY 2009 Q28.33%
FY 2009 Q38.74%
FY 2009 Q49.63%
FY 2010 Q18.68%
FY 2010 Q28.96%
FY 2010 Q310.01%
FY 2010 Q410.7%
FY 2011 Q19.27%
FY 2011 Q218.06%
FY 2011 Q38.93%
FY 2011 Q49.22%
FY 2012 Q18.94%
FY 2012 Q27.52%
FY 2012 Q39.41%
FY 2012 Q411.55%
FY 2013 Q110.53%
FY 2013 Q28.56%
FY 2013 Q39.95%
FY 2013 Q49.87%
FY 2014 Q113.91%
FY 2014 Q2—
FY 2014 Q3—
FY 2014 Q4—
FY 2015 Q1—
FY 2015 Q2—
FY 2015 Q3—
FY 2015 Q4—
FY 2016 Q1—
FY 2016 Q2—
FY 2016 Q3—
FY 2016 Q4—
FY 2017 Q1—
FY 2017 Q2—
FY 2017 Q3—
FY 2017 Q4—
FY 2018 Q1—
FY 2018 Q2—
FY 2018 Q3—
FY 2018 Q4—
FY 2019 Q1—
FY 2019 Q2—
FY 2019 Q3—
FY 2019 Q4—
FY 2020 Q1—
FY 2020 Q2—
FY 2020 Q3—
FY 2020 Q4—
FY 2021 Q123.59%
FY 2021 Q219.72%
FY 2021 Q320.4%
FY 2021 Q415.5%
FY 2022 Q118.78%
FY 2022 Q215.21%
FY 2022 Q314.03%
FY 2022 Q413.75%
FY 2023 Q112.06%
FY 2023 Q212.74%
FY 2023 Q316.03%
FY 2023 Q414.75%
FY 2024 Q112.87%
FY 2024 Q214.73%
FY 2024 Q315.37%
FY 2024 Q416.01%
FY 2025 Q114.58%
FY 2025 Q214.9%
FY 2025 Q314.53%
FY 2025 Q416.08%
FY 2026 Q115%
FY 2026 Q214.47%

P/E

× · TTM · Daily

35.94×
Thermo Fisher Scientific P/E. Monthly closing observations; inspect daily values with the chart arrow keys.
Close date× · TTM · DailyFinancials through
2012-03-3015.94×2011-12-31
2012-04-3015.74×2011-12-31
2012-05-3114.27×2011-12-31
2012-06-2914.68×2011-12-31
2012-07-3115.74×2011-12-31
2012-08-3119.87×2012-06-30
2012-09-2820.39×2012-06-30
2012-10-3121.16×2012-06-30
2012-11-3021.3×2012-09-29
2012-12-3121.37×2012-09-29
2013-01-3124.17×2012-09-29
2013-02-2822.67×2012-12-31
2013-03-2823.5×2012-12-31
2013-04-3024.79×2012-12-31
2013-05-3125.82×2013-03-30
2013-06-2824.75×2013-03-30
2013-07-3126.64×2013-03-30
2013-08-3025.22×2013-06-29
2013-09-3026.16×2013-06-29
2013-10-3127.76×2013-06-29
2013-11-2928.33×2013-09-28
2013-12-3131.28×2013-09-28
2014-01-3132.34×2013-09-28
2014-02-2834.98×2013-09-28
2014-03-3133.77×2013-09-28
2014-04-3032.02×2013-09-28
2014-05-3031.47×2014-03-29
2014-06-3031.76×2014-03-29
2014-07-3132.7×2014-03-29
2014-08-2932.71×2014-06-28
2014-09-3033.12×2014-06-28
2014-10-3131.99×2014-06-28
2014-11-2831.92×2014-09-27
2014-12-3130.93×2014-09-27
2015-01-3030.91×2014-09-27
2015-02-2727.72×2014-12-31
2015-03-3128.65×2014-12-31
2015-04-3026.8×2014-12-31
2015-05-2929.97×2015-03-28
2015-06-3030×2015-03-28
2015-07-3132.25×2015-03-28
2015-08-3125.56×2015-06-27
2015-09-3024.93×2015-06-27
2015-10-3026.66×2015-06-27
2015-11-3028.18×2015-09-26
2015-12-3128.89×2015-09-26
2016-01-2926.89×2015-09-26
2016-02-2926.32×2015-12-31
2016-03-3128.85×2015-12-31
2016-04-2929.39×2015-12-31
2016-05-3130.37×2016-04-02
2016-06-3029.57×2016-04-02
2016-07-2931.78×2016-04-02
2016-08-3130.22×2016-07-02
2016-09-3031.59×2016-07-02
2016-10-3129.2×2016-07-02
2016-11-3027.91×2016-10-01
2016-12-3028.11×2016-10-01
2017-01-3130.36×2016-10-01
2017-02-2831.41×2016-10-01
2017-03-3130.15×2016-12-31
2017-04-2832.45×2016-12-31
2017-05-3131.37×2017-04-01
2017-06-3031.67×2017-04-01
2017-07-3131.86×2017-04-01
2017-08-3132.48×2017-07-01
2017-09-2932.84×2017-07-01
2017-10-3133.64×2017-07-01
2017-11-3033.11×2017-09-30
2017-12-2932.62×2017-09-30
2018-01-3138.49×2017-09-30
2018-02-2835.83×2017-09-30
2018-03-2937.59×2017-12-31
2018-04-3038.3×2017-12-31
2018-05-3137.92×2017-12-31
2018-06-2937.72×2017-12-31
2018-07-3142.7×2017-12-31
2018-08-3143.53×2017-12-31
2018-09-2844.44×2017-12-31
2018-10-3142.54×2017-12-31
2018-11-3045.44×2017-12-31
2018-12-3140.75×2017-12-31
2019-01-3144.73×2017-12-31
2019-02-2835.87×2018-12-31
2019-03-2937.83×2018-12-31
2019-04-3038.34×2018-12-31
2019-05-3136.89×2018-12-31
2019-06-2840.58×2018-12-31
2019-07-3138.37×2018-12-31
2019-08-3039.67×2018-12-31
2019-09-3040.25×2018-12-31
2019-10-3141.73×2018-12-31
2019-11-2935.31×2019-09-28
2019-12-3136.54×2019-09-28
2020-01-3135.23×2019-09-28
2020-02-2831.71×2019-12-31
2020-03-3130.92×2019-12-31
2020-04-3036.49×2019-12-31
2020-05-2938.07×2020-03-28
2020-06-3039.5×2020-03-28
2020-07-3145.13×2020-03-28
2020-08-3146.07×2020-06-27
2020-09-3047.42×2020-06-27
2020-10-3050.81×2020-06-27
2020-11-3038.03×2020-09-26
2020-12-3138.09×2020-09-26
2021-01-2941.68×2020-09-26
2021-02-2628.17×2020-12-31
2021-03-3128.56×2020-12-31
2021-04-3029.43×2020-12-31
2021-05-2823.52×2021-04-03
2021-06-3025.27×2021-04-03
2021-07-3027.06×2021-04-03
2021-08-3125.57×2021-07-03
2021-09-3026.32×2021-07-03
2021-10-2929.16×2021-07-03
2021-11-3029.33×2021-10-02
2021-12-3130.93×2021-10-02
2022-01-3126.94×2021-10-02
2022-02-2827.96×2021-12-31
2022-03-3130.35×2021-12-31
2022-04-2928.42×2021-12-31
2022-05-3129.17×2021-12-31
2022-06-3027.92×2021-12-31
2022-07-2930.75×2021-12-31
2022-08-3128.02×2021-12-31
2022-09-3026.07×2021-12-31
2022-10-3126.41×2021-12-31
2022-11-3031.47×2022-10-01
2022-12-3030.93×2022-10-01
2023-01-3132.04×2022-10-01
2023-02-2830.48×2022-12-31
2023-03-3132.43×2022-12-31
2023-04-2831.22×2022-12-31
2023-05-3132.75×2023-04-01
2023-06-3033.61×2023-04-01
2023-07-3135.34×2023-04-01
2023-08-3137.78×2023-07-01
2023-09-2934.33×2023-07-01
2023-10-3130.16×2023-07-01
2023-11-3032.38×2023-09-30
2023-12-2934.67×2023-09-30
2024-01-3135.2×2023-09-30
2024-02-2936.9×2023-12-31
2024-03-2837.62×2023-12-31
2024-04-3036.81×2023-12-31
2024-05-3136.15×2024-03-30
2024-06-2835.19×2024-03-30
2024-07-3139.03×2024-03-30
2024-08-3039.14×2024-03-30
2024-09-3039.37×2024-03-30
2024-10-3134.77×2024-03-30
2024-11-2933.71×2024-03-30
2024-12-3133.11×2024-03-30
2025-01-3138.04×2024-03-30
2025-02-2831.98×2024-12-31
2025-03-3130.08×2024-12-31
2025-04-3025.94×2024-12-31
2025-05-3024.35×2024-12-31
2025-06-3024.51×2024-12-31
2025-07-3128.27×2024-12-31
2025-08-2929.79×2024-12-31
2025-09-3029.32×2024-12-31
2025-10-3134.3×2024-12-31
2025-11-2833.99×2025-09-27
2025-12-3133.34×2025-09-27
2026-01-3033.29×2025-09-27
2026-02-2729.38×2025-12-31
2026-03-3127.71×2025-12-31
2026-04-3027.01×2025-12-31
2026-05-2926.83×2026-03-28
2026-06-3027.31×2026-03-28
2026-07-3131.28×2026-03-28
2026-08-3132.86×2026-06-27
2026-09-2535.94×2026-06-27

ROIC

% · Annual / TTM

8.72%
Thermo Fisher Scientific ROIC. Reported fiscal history.
Fiscal period% · Annual / TTM
FY 2009 Q2—
FY 2009 Q3—
FY 2009 Q4—
FY 2010 Q1—
FY 2010 Q2—
FY 2010 Q3—
FY 2010 Q46.82%
FY 2011 Q1—
FY 2011 Q26.29%
FY 2011 Q35.88%
FY 2011 Q45.99%
FY 2012 Q16.24%
FY 2012 Q26.62%
FY 2012 Q36.17%
FY 2012 Q46.87%
FY 2013 Q1—
FY 2013 Q2—
FY 2013 Q3—
FY 2013 Q47.21%
FY 2014 Q16.12%
FY 2014 Q26.29%
FY 2014 Q37%
FY 2014 Q48.22%
FY 2015 Q1—
FY 2015 Q2—
FY 2015 Q3—
FY 2015 Q4—
FY 2016 Q1—
FY 2016 Q2—
FY 2016 Q3—
FY 2016 Q4—
FY 2017 Q1—
FY 2017 Q2—
FY 2017 Q3—
FY 2017 Q46.6%
FY 2018 Q16.55%
FY 2018 Q26.94%
FY 2018 Q36.65%
FY 2018 Q47.61%
FY 2019 Q17.95%
FY 2019 Q28.7%
FY 2019 Q38.93%
FY 2019 Q49.32%
FY 2020 Q19.12%
FY 2020 Q29.26%
FY 2020 Q311.95%
FY 2020 Q415.12%
FY 2021 Q118.37%
FY 2021 Q219.7%
FY 2021 Q319.56%
FY 2021 Q414.97%
FY 2022 Q114.49%
FY 2022 Q214.3%
FY 2022 Q313.92%
FY 2022 Q410.82%
FY 2023 Q19.14%
FY 2023 Q28.78%
FY 2023 Q39.03%
FY 2023 Q49.12%
FY 2024 Q18.56%
FY 2024 Q28.74%
FY 2024 Q38.44%
FY 2024 Q48.85%
FY 2025 Q18.9%
FY 2025 Q28.85%
FY 2025 Q38.43%
FY 2025 Q48.97%
FY 2026 Q18.57%
FY 2026 Q28.72%

Capital allocation

% of tracked cash uses

$1,625M
Thermo Fisher Scientific capital allocation. Quarterly values. Missing values are unavailable.
PeriodCapexAcquisitionsBuybacksDividendsDebt repaymentsTracked uses
FY 2009 Q219.94% · $31.8M80.06% · $127.7MUnavailableUnavailableUnavailable100% · $159.5M
FY 2009 Q381.84% · $42.8M18.16% · $9.5M0% · $0MUnavailable0% · $0M100% · $52.3M
FY 2009 Q46.93% · $81.7M40.87% · $481.8M0% · $0MUnavailable52.21% · $615.5M100% · $1,179M
FY 2010 Q110.4% · $50.6M47.08% · $229.1M0% · $0MUnavailable42.52% · $206.9M100% · $486.6M
FY 2010 Q28.36% · $58.4M8.4% · $58.7M26.84% · $187.5MUnavailable56.39% · $393.9M100% · $698.5M
FY 2010 Q38.1% · $64.6M32.31% · $257.6M59.58% · $475MUnavailable0% · $0M100% · $797.2M
FY 2010 Q418.28% · $91.9M12.09% · $60.8M69.62% · $350MUnavailable0% · $0M100% · $502.7M
FY 2011 Q19.65% · $63.7M3.59% · $23.7M81.43% · $537.5MUnavailable5.33% · $35.2M100% · $660.1M
FY 2011 Q22.14% · $59.2M74.68% · $2,067.6M8.13% · $225MUnavailable15.05% · $416.8M100% · $2,768.6M
FY 2011 Q31.61% · $62.6M92.62% · $3,608.1M5.78% · $225MUnavailable0% · $0M100% · $3,895.7M
FY 2011 Q418.79% · $81MUnavailable81.21% · $350MUnavailable0% · $0M100% · $431M
FY 2012 Q118.76% · $69.4M0.14% · $0.5M81.1% · $300M0% · $0M0% · $0M100% · $369.9M
FY 2012 Q216.69% · $65.3M45.55% · $178.2M25.56% · $100M12.19% · $47.7M0% · $0M100% · $391.2M
FY 2012 Q35.36% · $76M63.06% · $893.7M28.22% · $400M3.36% · $47.6MUnavailable100% · $1,417.3M
FY 2012 Q420.38% · $104.4M2.15% · $11M68.32% · $350M9.15% · $46.9MUnavailable100% · $512.3M
FY 2013 Q130.9% · $66M1.78% · $3.8M42.04% · $89.8M25.28% · $54MUnavailable100% · $213.6M
FY 2013 Q254.49% · $65.6M0.75% · $0.9M0% · $0M44.77% · $53.9MUnavailable100% · $120.4M
FY 2013 Q350.63% · $56.3M0.72% · $0.8M0% · $0M48.65% · $54.1MUnavailable100% · $111.2M
FY 2013 Q461.13% · $94.5M3.82% · $5.9M0% · $0M35.06% · $54.2MUnavailable100% · $154.6M
FY 2014 Q10.79% · $104.7M98.79% · $13,056.3M0% · $0M0.42% · $54.9MUnavailable100% · $13,215.9M
FY 2014 Q255.8% · $75.5MUnavailable0% · $0M44.2% · $59.8MUnavailable100% · $135.3M
FY 2014 Q359.51% · $90.7M1.05% · $1.6M0% · $0M39.44% · $60.1MUnavailable100% · $152.4M
FY 2014 Q412.47% · $156.7M0.32% · $4M0% · $0M4.78% · $60M82.43% · $1,035.7M100% · $1,256.4M
FY 2015 Q15.38% · $97.2M16.52% · $298.6M27.65% · $500M3.36% · $60.8M47.09% · $851.4M100% · $1,808M
FY 2015 Q211.1% · $95.3M0% · $0M0% · $0M6.96% · $59.7M81.94% · $703.3M100% · $858.3M
FY 2015 Q39.22% · $101M0.68% · $7.4M0% · $0M5.5% · $60.2M84.6% · $926.3M100% · $1,094.9M
FY 2015 Q46.89% · $129.4M20.7% · $388.6M0% · $0M3.19% · $59.9M69.21% · $1,299.2M100% · $1,877.1M
FY 2016 Q15.21% · $115.1M46.73% · $1,032.4M45.27% · $1,000M2.73% · $60.3M0.06% · $1.4M100% · $2,209.2M
FY 2016 Q26.36% · $114.8M0.04% · $0.7M0% · $0M3.27% · $59.1M90.33% · $1,631M100% · $1,805.6M
FY 2016 Q31.64% · $81M83.48% · $4,119.9M0% · $0M1.21% · $59.8M13.67% · $674.7M100% · $4,935.4M
FY 2016 Q45.33% · $133.5M1.41% · $35.4M9.98% · $250M2.36% · $59.2M80.92% · $2,027.1M100% · $2,505.2M
FY 2017 Q15.64% · $93.4M18.15% · $300.7M30.19% · $500M3.57% · $59.1M42.45% · $703.2M100% · $1,656.4M
FY 2017 Q28.55% · $88M0.61% · $6.3M24.3% · $250M5.71% · $58.7M60.82% · $625.7M100% · $1,028.7M
FY 2017 Q31.35% · $111.4M83.1% · $6,853.2M0% · $0M0.72% · $59.3M14.83% · $1,222.8M100% · $8,246.7M
FY 2017 Q419.78% · $215.2M6.05% · $65.8M0% · $0M5.5% · $59.9M68.67% · $747.3M100% · $1,088.2M
FY 2018 Q117.15% · $118M8.28% · $57M0% · $0M8.72% · $60M65.84% · $453M100% · $688M
FY 2018 Q215.86% · $183M0.17% · $2M0% · $0M5.98% · $69M77.99% · $900M100% · $1,154M
FY 2018 Q314.57% · $173M0% · $0M21.06% · $250M5.81% · $69M58.55% · $695M100% · $1,187M
FY 2018 Q426.22% · $284M44.04% · $477M23.08% · $250M6.28% · $68M0.37% · $4M100% · $1,083M
FY 2019 Q119.69% · $201M0.1% · $1M73.46% · $750M6.66% · $68M0.1% · $1M100% · $1,021M
FY 2019 Q211.09% · $220M84.97% · $1,685M0% · $0M3.83% · $76M0.1% · $2M100% · $1,983M
FY 2019 Q310.84% · $216M0.05% · $1M0% · $0M3.86% · $77M85.25% · $1,699M100% · $1,993M
FY 2019 Q44.87% · $289M2.63% · $156M12.65% · $750M1.28% · $76M78.56% · $4,658M100% · $5,929M
FY 2020 Q113.79% · $253M0.22% · $4M81.79% · $1,500M4.14% · $76M0.05% · $1M100% · $1,834M
FY 2020 Q275.35% · $269MUnavailable0% · $0M24.37% · $87M0.28% · $1M100% · $357M
FY 2020 Q331.47% · $366M0% · $0M0% · $0M7.48% · $87M61.05% · $710M100% · $1,163M
FY 2020 Q482.65% · $586M4.94% · $35M0% · $0M12.27% · $87M0.14% · $1M100% · $709M
FY 2021 Q19.15% · $628M19.57% · $1,343M29.15% · $2,000M1.27% · $87M40.86% · $2,804M100% · $6,862M
FY 2021 Q274.38% · $540M11.29% · $82M0% · $0M14.19% · $103M0.14% · $1M100% · $726M
FY 2021 Q372.58% · $524M13.02% · $94M0% · $0M14.13% · $102M0.28% · $2M100% · $722M
FY 2021 Q43% · $831M64.44% · $17,876M0% · $0M0.37% · $103M32.19% · $8,931M100% · $27,741M
FY 2022 Q120.27% · $640M1.27% · $40M63.33% · $2,000M3.26% · $103M11.87% · $375M100% · $3,158M
FY 2022 Q281.22% · $506M0% · $0M0% · $0M18.78% · $117M0% · $0M100% · $623M
FY 2022 Q382.26% · $547MUnavailable0% · $0M17.74% · $118M0% · $0M100% · $665M
FY 2022 Q432.99% · $550M0% · $0M59.99% · $1,000M7.02% · $117M0% · $0M100% · $1,667M
FY 2023 Q17.29% · $458M43.06% · $2,704M47.78% · $3,000M1.86% · $117M0% · $0M100% · $6,279M
FY 2023 Q219.37% · $284M3.21% · $47M0% · $0M9.21% · $135M68.21% · $1,000M100% · $1,466M
FY 2023 Q313.97% · $332M38.26% · $909M0% · $0M5.68% · $135M42.09% · $1,000M100% · $2,376M
FY 2023 Q49.37% · $405M0% · $0M0% · $0M3.15% · $136M87.49% · $3,782M100% · $4,323M
FY 2024 Q19.97% · $347M0% · $0M86.16% · $3,000M3.88% · $135M0% · $0M100% · $3,482M
FY 2024 Q266.89% · $301M0% · $0M0% · $0M33.11% · $149M0% · $0M100% · $450M
FY 2024 Q35.84% · $272M67.2% · $3,132M0% · $0M3.22% · $150M23.75% · $1,107M100% · $4,661M
FY 2024 Q411.63% · $480M0% · $0M24.22% · $1,000M3.61% · $149M60.55% · $2,500M100% · $4,129M
FY 2025 Q110.81% · $362M0% · $0M59.72% · $2,000M4.45% · $149M25.02% · $838M100% · $3,349M
FY 2025 Q223.65% · $294M0% · $0M0% · $0M13.03% · $162M63.31% · $787M100% · $1,243M
FY 2025 Q37.26% · $404M72.52% · $4,037M17.3% · $963M2.93% · $163M0% · $0M100% · $5,567M
FY 2025 Q432.05% · $465M0% · $0M2.55% · $37M11.16% · $162M54.24% · $787M100% · $1,451M
FY 2026 Q12.72% · $376M64.19% · $8,872M21.7% · $3,000M1.17% · $162M10.22% · $1,412M100% · $13,822M
FY 2026 Q227.69% · $450M0% · $0M61.54% · $1,000M10.77% · $175M0% · $0M100% · $1,625M

Sources and calculations

Company filings · USD · Last checked 2026-10-18. Missing inputs remain unavailable. Your chart selection and layout are saved in this browser for Thermo Fisher Scientific.

All charts share the selected dates. Quarterly/Yearly changes fiscal charts; valuation keeps completed daily closes on a published TTM basis. Later restatements can delay that basis. Historical mean, median and pricing labels use the selected range and do not estimate intrinsic fair value.

SBC deduction is an optional economic-cost scenario for FCF-based metrics. Missing SBC never becomes zero.

Revenue
Reported revenue from company filings.
Free cash flow
Operating cash flow − reported cash capital investment. PPE purchases are preferred; the productive-assets fallback also includes software and intangibles. Reflects the SBC option and can differ from issuer-defined FCF.
Net margin
Reported net income / revenue × 100.
P/E
Completed closing price × diluted shares / TTM earnings attributable to common shareholders.
ROIC
NOPAT / average invested capital × 100. NOPAT = operating income × (1 − effective tax rate). Invested capital = equity including noncontrolling interests + debt − cash and equivalents. Average uses period end and one year earlier.
Capital allocation
Reported cash uses as a percentage of tracked uses. Missing categories remain unavailable; SBC is noncash and excluded.
Reported revenue and sources